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E-mail address: ahmed.abdel-aziz@guc.edu.eg (A.ImicroRNAs aberrant behavior in heptocellular carcinoma (HCC) plays a major role in HCC pathogen-
esis. miR-615-5p expression has never been evaluated in HCC. We showed that miR-615-5p was pref-
erentially expressed in HCC, cirrhotic liver tissues and HCC cell lines, but undetected in normal
livers. Forced miR-615-5p expression in HCC cell lines led to signiﬁcant decrease in cell growth
and migration. In-silico predication revealed insulin-like growth factor-II (IGF-II) as a potential
downstream target for miR-615-5p. Forcing the expression of miR-615-5p showed downregulation
of IGF-II mRNA, as well as inhibition of the luciferase activity in a luciferase reporter vector harbor-
ing the IGF-II-30UTR target sequence. miR-615-5p acts as tumor-suppressor in HCC through targeting
IGF-II.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Complexity of the pathogenesis of hepatocellular carcinoma
(HCC) evoked researches to look what’s beyond the genetic disrup-
tion in the disease which is the epigenetic regulation of HCC path-
ogenesis and progression. Hepatocarcinogenesis is governed by
many epigenetic regulatory processes like hypermethylation of tu-
mor suppressor genes FBP1, RASSF1 and SOX17 that was evidenced
frequently in HCC tissues leading to their silencing and increased
cellular proliferation, cell cycle progression and nuclear accumula-
tion of mitogenic proteins [1–3]. On the other hand, hypomethyla-
tion of oncogenes CD147 and LINE-1 in HCC that led to increased
metastasis and poor survival [4,5]. Emerging evidence indicates
that the newly discovered non-coding short RNAs (microRNAs)
deregulation have contributed greatly to the epigenetic-based
hepatocarcinogensies [6]. microRNAs (miRNA) originate from in-
tronic or polycistronic sequences and were proved to have roles
in cellular differentiation, metabolism, proliferation and malignant
transformation [7]. Some microRNAs were found to be overexpres-
sed in HCC and were classiﬁed to be oncogenic in nature as miR-
155 that promoted cellular invasion and proliferation in HCC cellchemical Societies. Published by E
. Abdelaziz).lines[8,9]. Moreover, miR-210 was also described as an oncomiR
in promoting HCC cell invasion and migration [10]. Antagonizing
the expression of miR-221 in HCC cell lines, that is clustered as
oncogenic miRNA lead to reduced cellular proliferation [11]. Some
other microRNAs showed potent anti-tumorgenic effects where
they were mostly downregulated in HCC tissues compared to
healthy liver tissues. For example, the liver speciﬁc miR-122; was
found to be downregulated in HCC tissues, while its intended over-
expression showed anti-proliferative effects in human HCC cell
lines [12]. Also, miR-520e, miR-223 and miR-375 were downregu-
lated in HCC tissues. Upon their intended overexpression, they
showed potent proliferation-inhibition, cell cycle arrest, apoptosis
and clonogenicity inhibition in HCC cell lines [13–15]. miR-615-5p
is a very novel microRNA that was once analyzed in prostate cancer
cell lines where it showed high expression [16]. However the role
of miR-615-5p has never been studied and its role in carcinogene-
sis has never been investigated which makes it a potential target
for further analysis. Hence our study aimed at investigating miR-
615-5p in HCC in an approach to screen for the presence of miR-
615-5p in healthy, cirrhotic and cancerous liver tissues as well as
HCC cell lines followed by its functional analysis by inducing its
overexpression and inhibition in HuH-7 and HepG2 cell lines. We
have simultaneously screened and manipulated the expression of
the recently characterized hepato-oncogenic miR-155 as standard
control for our results.lsevier B.V. All rights reserved.
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2.1. Study patients
This study included 20 HCC patients who underwent liver
transplant surgery in the Kasr El Einy Hospital, Cairo University,
Egypt. Nine cirrhotic tissues were taken from some of the same
HCC patients with focal HCC lesions. Fifteen healthy liver biopsies
were obtained. The study was approved by the Cairo University’s
ethical review committee. All participants gave their written in-
formed consent. Most of the patients (75.5%) hadmore than one fo-
cal lesion as indicated in the pathology report and were subjected
to clinical assessment as shown in Table 1.
2.2. Cell cultures
HuH-7 and HepG2 cells were maintained in Dulbecco’s modi-
ﬁed Eagle’s medium(DMEM) (Lonza, Switzerland) supplemented
with 4.5 g/l glucose, 4 mmol/l L-glutamine, 10% fetal bovine serum
and Mycozap (1:500, Lonza, Switzerland) at 37 C in 5% CO2
atmosphere.
2.3. Transfection of microRNA oligonucleotides
HuH-7 and HepG2 cell lines were transfected with mimics and
inhibitors of miR-615-5p, miR-155 and scrambled microRNAs
(Qiagen, Germany). For examining the effect of miR-615-5p on
Insulin-like growth factor (IGF-II) transcript expression, siRNAs
against IGF-II were used (FlexiTube Gene Solution IGF-II-speciﬁc
siRNAs, Qiagen, Germany). All transfection experiments were car-
ried out in triplicates using HiPerfect Transfection Reagent (Qiagen,
Germany) according to the manufacture’s protocol and experi-
ments were repeated 3 times. Cells that were only exposed to
transfection reagent were designated as Mock cells, cells transfec-
ted with scrambled microRNAs were designated as Scr-miR cells,
and cells transfected with siRNAs against IGF-II were designated
as siIGF-II cells. Cells transfected with miR-615-5p or miR-155
mimics were designated as miR-615-5p cells or miR-155 cells,
respectively and cells transfected with the respective miR-615-5p
or miR-155 inhibitor were designated as anti-miR-615-5p or
anti-miR-155 cells, respectively.
2.4. mRNA and microRNA extraction from liver biopsies and HCC cell
lines
mRNAs and microRNAs were extracted from liver biopsies and
HCC cell lines. Fresh liver samples (HCC, cirrhotic and healthy tis-
sues) were collected during surgery and were immediately snap-
frozen in liquid nitrogen. The specimens were manually pulverized
in liquid nitrogen and about 100 mg of tissues powder were used
for large and small RNA extraction using mirVana miRNA Isolation
Kit (Ambion, USA) according to the manufacture’s protocol. HCC
cell lines were harvested 48 h after transfection according to
HiPerfect Transfection Reagent protocol: 150 ng oligonucleotidesTable 1
Characteristic features of hepatocellular carcinoma (HCC) patients.
Age: mean 49
Sex: male/female 19/1
Aspartate aminotransferase (AST) (U/l) 100.5 ± 65.8
Alanine aminotransferase (ALT) (U/l) 85.6 ± 95.6
Alkaline Phosphatase (U/l) 110.2 ± 60.7
Serum albumin (g/dl) 4.6 ± 1.5
Serum AFP (ng/ml) 155.7 ± 22.3
HCV Ab 100% (20 HCC patients)were used for HuH-7 and 300 ng oligonucleotides for HepG2 cells
transfection in 6-well plate. RNA yield was quantiﬁed with a spec-
trophotometer and RNA integrity was tested by 18S rRNA bands
detection on 1% agarose gel electrophoresis. RNA samples with
Optical Density 260/280 more than 2 were excluded from the
study.
2.5. miRNA and mRNA quantiﬁcation
The extracted microRNAs were reverse transcribed into single
stranded complementary DNA (cDNA) using TaqMan MicroRNA
Reverse Transcription Kit (ABI, USA) and speciﬁc primers for hsa-
miR-615-5p, hsa-miR-155 and RNU6B. IGF-II mRNA was reverse
transcribed into cDNA using the High-capacity cDNA Reverse Tran-
scription Kit (ABI, USA) according to the manufacturer’s instruc-
tion. Relative expression of miR-615-5p and miR-155 and RNU6B
(for normalization) as well as IGF-II and GAPDH (for normalization)
was quantiﬁed using TaqMan Real-Time Q-PCR (ABI Assay IDs:
002353, 002623, 001093, Hs01005963_m1 and Hs00266705_g1,
respectively) using StepOne™ Systems (ABI, USA). Relative expres-
sion was calculated using the 2DDCt method. All PCR reactions
including controls were run in duplicate reactions.
2.6. Cell proliferation and growth assays (BrdU and MTT)
For BrdU assay; HuH-7 and HepG2 cells were seeded 24 h prior
to transfection in black 96-well plates and transfected with 12.5 ng
and 25 ng oligonucleotides, respectively (according to HiPerfect
protocol) with initial constant cell count, 5  104 cells/well.
Forty-eight hours after oligonucleotides transfection, cells were la-
beled with BrdU labeling reagent for 4 h (with ﬁnal concentration
100 lM) using the Cell Proliferation ELISA kit (Roche Applied Bio-
systems, Germany). Cells were then ﬁxed using FixDenate for
30 min then incubated with Anti-BrdU POD (with ﬁnal concentra-
tion 10 lM) for 90 min. For MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay; 10,000 HuH-7 and HepG2
cells were seeded in 200 ll media per well in a 96 well plate and
incubated 24 h prior to transfection with 12.5 ng and 25 ng oligo-
nucleotides, respectively (according to HiPerfect protocol). Forty-
eight hours post-transfection, 20 ll MTT solution (5 mg/ml MTT
in PBS) was added to each well. After incubation for 5 h, formazan
(MTT metabolic product) was resuspended in 200 ll DMSO. Color-
imetric measurements and absorbance were performed usingWal-
lac 1420 Victor2 Multilabel Counter (Perkin Elmer, USA). All cell
proliferation experiments were done in triplicates and repeated
three times.
2.7. Cell scratch wound healing assay
HuH-7 and HepG2 cells were left for 80–90% conﬂuence in 6-
well plates. Forty-eight hours post-transfection, 5 scratches/well
were made in each plate with 200 ll pipette tip. Detached cells
were washed out using serum-free medium. Medium was then
added and culture plates were incubated at 37 C. Forty-eight
hours post-scratching, migration was documented and wound clo-
sure was quantiﬁed with Image J software (http://rsbweb.nih.gov/
ij/download.html) by measuring the surface area covered by the
cells. All Scratch assays were done in duplicates (two wells/test
which represents 10 scratches/test) and repeated three times.
2.8. Bioinformatics
Using bioinformatics algorithms; microrna.org (www.micror-
na.org), miRDB (www.mirdb.org/miRDB/), DIANA Lab (www.dia-
na.cslab.ece.ntua.gr/), and Target Scan (www.targetscan.org/)
putative downstream targets for miR-615-5p have been predicted.
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The predicted target site for miR-615-5p at IGF-II 30UTR was de-
signed as oligonucleotides and ﬂanked by SacI and XbaI restriction
sites; Sense: 50GAGCTCTAGGTACCGCAAAGAGAAAAGAAGGACCCCA-
TCTAGA30and antisense: 50TCTAGATGGGGTCCTTCTTTTCTCTTTGC-
GGTACCATGAGCC-TC 30. pmirGLO Dual-Luciferase miRNA Target
Expression Vector (Promega, Germany) was double digested with
SacI and XbaI restriction enzymes (Takara, Japan) at 37 C for 4 h
followed by enzymes deactivation at 65 C, then blunted by T4
DNA polymerase enzyme (Fermentas, USA) at 11 C for 20 min.
Sense and antisense strands of the designed oligonucleoitdes were
annealed at 90 C for 3 min then incubated at 37 C for 15 min. An-
nealed double stranded oligonucleotides were ligated to the pmiR-
GLO vector double digest using T4 DNA ligase (Fermentas, USA) at
22 C with overnight incubation. HuH-7 cells were transfected by
lipofection; Superfect transfection reagent (Qiagen, Germany) with
pmiRGLO+/insert in presence or absence of miR-615-5p mimics
and inhibitors. After 48 h luciferase assay was performed using
Luciferase Reporter System (Promega, Germany) by adding 100 ll
1 cell lysis reagent per well in 24 well plate followed by transfer-
ring 20 ll of cell lysate into 96 well plate. Luciferase reagent was
added and chemilumenicence was measured within 10 s.
3. Statistical analysis
All data are presented as mean with SEM. Statistical signiﬁcance
of the data was analyzed by performing One-way analysis of
variance (ANOVA) or Paired Student t tests. The speciﬁc types of
tests, when applicable, are indicated in the ﬁgure legends.
⁄⁄⁄P < 0.001, ⁄⁄P < 0.01, ⁄P < 0.05 and ns = statistically not signiﬁcant.
4. Results
4.1. miR-615-5p and miR-155 screening in liver tissues and HCC cell
lines
miR-615-5p was undetectable in 100% of healthy liver tissues.
While its expression was signiﬁcantly high in all HCC biopsies
(n = 20) and cell lines (HuH-7 and HepG2) compared to cirrhotic
tissues (P = 0.007, P < 0.0001 and P = 0.0013, respectively; Fig. 1a).
miR-155 showed a signiﬁcant higher expression in HCC (n = 20)
and cirrhotic tissues (n = 9) as well as HCC cell lines compared toFig. 1. miR-615-5p and miR-155 screening in liver tissues and HCC cell lines; (a) miR-615
in HCC tissues and HuH-7 and HepG2 cell lines compared to cirrhotic tissues. (b) miR-15
HepG2 cell lines compared to healthy tissues. One-way analysis of variance (ANOVA) whealthy tissues (P = 0.0003, P = 0.0001 and P < 0.0001, respec-
tively). It also worth mentioning that miR-155 was markedly ele-
vated in HCC tissues compared to other cirrhotic tissues
(P = 0.0001).
4.2. Transfection efﬁciency of miR-615-5p and miR-155
oligonucleotides
Mimicked HuH-7 and HepG2 cells with miR-615-5p and miR-
155 mimics showed upregulation up to 47.12, 61.2 (P = 0.0025
and P = 0.003, respectively), 20 and 17 (P < 0.0001 and P < 0.0001,
respectively) fold increase compared to their respective mock cells
(Fig. 2).
4.3. Impact of miR-615-5p and miR-155 on cellular proliferation and
growth
BrdU incorporation assay was used for investigating cell prolif-
eration and growth. Mimicking of miR-615-5p in HuH-7 and
HepG2 cells showed a signiﬁcant decrease in cellular proliferation
(P = 0.0002 and P = 0.0044, respectively) compared to negative
control and mock cells while miR-155 promoted HuH-7 and HepG2
cell proliferation signiﬁcantly (P = 0.0017 and P = 0.0292, respec-
tively). Recovery experiments using antagomirs for both miR-
615-5p and miR-155 showed signiﬁcant recovery of the inhibitory
effect of miR-615-5p on proliferation and decrease in the prolifer-
ative effect of miR-155 on HuH-7 and HepG2 (P < 0.0001, P =
0.0004) and (P < 0.0001, P < 0.0001), respectively (Fig. 3a).
MTT assay was used for investigating cell viability and growth.
Forced expression of miR-615-5p in HuH-7 and HepG2 cell lines
showed marked repression in cellular growth (P = 0.0471 and
P = 0.0072, respectively) compared to mock cells while miR-155
showed increased HuH-7 and HepG2 cell growth (P = 0.0102 and
0.0002, respectively). Recovery experiments using inhibitors for
both miR-615-5p and miR-155 showed reversal of the inhibitory
effect of miR-615-5p and stimulatory effect of miR-155 on HuH-
7 and HepG2 cell growth (P = 0.1185 and P = 0.0207) and (P =
0.0038 and P = 0.0001), respectively (Fig. 3b).
4.4. Impact of miR-615-5p and miR-155 on cellular migration
Images for two-dimensional scratch-migration assay were doc-
umented at ﬁvefold magniﬁcation[17]. Transfection of miR-615-5p-5p expression was undetectable in healthy liver biopsies with increased expression
5 showed increased expression in HCC and cirrhotic tissues as well as in HuH-7 and
as performed.
Fig. 2. Transfection efﬁciency of miR-615-5p and miR-155 oligonucleotides; (a) miR-615-5p mimics signiﬁcantly increased its expression in HuH-7 and HepG2 cells
compared to mock control. (b) miR-155 mimics elevated its expression in HuH-7 and HepG2 cells compared to mock controls. Paired t test was performed.
Fig. 3. Impact of miR-615-5p and miR-155 on cellular growth; (a) BrdU assay; mimics of miR-615-5p signiﬁcantly suppressed cellular proliferation and growth in HuH-7 and
HepG2 cells compared to controls. While mimics of miR-155 markedly promoted proliferation compared to controls. Inhibitors of miR-615-5p signiﬁcantly promoted cellular
proliferation compared to miR-615-5p mimicked cells while inhibitors of miR-155 signiﬁcantly repressed proliferation compared to miR-155 mimicked cells. (b) MTT assay;
In HuH-7 and HepG2 cells, miR-615-5p mimics markedly inhibited cellular growth and viability in contrast to miR-155 that signiﬁcantly increased cellular growth compared
to mock cells. Inhibitors of miR-615-5p improved cellular growth compared to miR-615-5p mimicked cells while anti-miR-155 cells showed repressed growth compared to
miR-155 cells. One-way analysis of variance (ANOVA) was performed for statistical analysis.
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7 and HepG2 cells covering 77.86% and 45.3% of the original
scratch compared to mock and Scr-miR with original scratch cov-
erage of (84.2%, 82.7%) and (100%, 100%) in both cell lines respec-tively. While miR-155 mimics resulted in promotion of tumor cell
migration in HuH-7 and HepG2 cells covering 89% and 100% of the
original scratch compared to mock and Scr-miR with original
scratch coverage of (84.2%, 82.7%) and (100%, 100%) in both cell
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rescued using miR-615-5p anatgomirs in HuH-7 and HepG2 cells,
while migration induction by miR-155 was repressed using miR-
155 antagomirs (Fig. 4).
4.5. Bioinformatics
miR-615-5p accession number and mature sequences were re-
trieved using miRBase database (http://www.mirbase.org/). In sil-
ico predictions was carried out using 4 different software, IGF-II
was found to be a predicted target for miR-615-5p. miR-615-5p
was found to hit IGF-II at 5 different regions by the same seed se-
quence (Fig. 5a). Binding scores given by softwares representing
the hybridization energies exerted for miR-615-5p-IGF-II binding
are shown in Fig. 5b.
4.6. IGF-II transcript as a putative target of miR-615-5p
Mimicking of miR-615-5p in HuH-7 and HepG2 cells resulted in
a signiﬁcant downregulation of IGF-II mRNA levels (P = 0.0001 and
P < 0.0001, respectively) compared to controls (Fig. 6). Inhibitors of
miR-615-5p in HuH-7 and HepG2 cells resulted in a marked in-
crease in IGF-II mRNA levels compared to miR-615-5p mimicked
cells (P < 0.0001 and P < 0.0001, Fig. 6).
4.7. Correlation analysis between miR-615-5p and IGF-II mRNA
expression in HCC tissues
IGF-II mRNA was quantiﬁed in all HCC tissues and correlated to
miR-615-5p expression in the same patients. Using Pearson statis-
tical method of correlation, miR-615-5p expression was found to
be inversely correlated with IGF-II transcript expression in all
HCC tissues studied with Pearson r = 0.468 (P = 0.0371, Fig. 7).
4.8. IGF-II is a direct target of miR-615-5p
To conﬁrm that miR-615-5p directly targets the 30UTR of IGF-II,
30UTR target region was inserted downstream to luciferase repor-
ter gene in pmiRGLO vector. Experiments were carried out byFig. 4. Impact of miR-615-5p and miR-155 on cellular Migration; (a) miR-615-5p mim
markedly induced migration compared to the original scratch. Inhibitors of miR-615-5p
while miR-155 inhibitors suppressed migration signiﬁcantly compared to miR-155 mimic
cells while miR-155 mimics markedly induced migration that reached complete closur
migration with complete closure of the scratch compared to miR-615-5p mimicked cells
mimicked cells. One-way analysis of variance (ANOVA) was performed for statistical antrasnfecting HuH-7 cells with either empty pmiRGLO vector or
the vector with the miR-615-5p target region insert. miR-615-5p
mimics and inhibitors were co-transfected with both vectors. Upon
miR-615-5p mimics co-transfection, luciferase activity was inhib-
ited by 19.4% in cells with the pmiRGLO + insert compared to cells
transfected with the pmiRGLO–insert (P < 0.0001). Upon miR-615-
5p inhibitors co-transfection, luciferase activity was increased by
9% compared to cells transfected pmiRGLO-insert and by 28% com-
pared to pmiRGLO + insert co-transfected with miR-615-5pmimics
(P = 0.0007). The luciferase experiments were done in triplicates.
5. Discussion
Several microRNAs have shown elevated expression in cancer-
ous tissues compared to normal liver tissue like miRNA-135a and
miR-423 that showed abundant expression in HCC compared to
normal liver tissues, and were found to promote tumorgenesis by
increasing the metastatic and invasive behaviors in vitro as well
as promoting cell growth and cell cycle progression [17,18]. In con-
trast to these ﬁndings, some microRNAs have shown lower expres-
sion in HCC tissues compared to normal tissues and their intended
overexpression suppressed HCC proliferation and migration
greatly like miR-122 and miR-199a/b-3p [19,20]. While in a third
scenario some microRNAs showed no expression in normal tissues
and were re-expressed in cancerous tissues as miR-615. miR-615
was overexpressed in prostate cancer and disappeared from nor-
mal prostate epithelial cells [16]. miR-615-5p has never been
investigated in HCC and it is still query whether it has protumor-
genic or anti-tumorgenic effects. For the ﬁrst time, we identiﬁed
that miR-615-5p is expressed in 100% of the HCC tissues and cell
lines as well as cirrhotic tissues but was undetectable in 100% of
healthy liver tissues. In order to validate these results, we have
chosen miR-155 as a positive control as it was proven to have a po-
sitive proliferative and migratory effect in HCC [8,9]. miR-155 was
found to be signiﬁcantly upregulated in all HCC as well as cirrhotic
tissues compared to healthy liver tissues. To analyze the impact of
miR-615-5p on hepatocarcinogenesies, we ectopically induced the
expression of miR-615-5p in different HCC cell lines. This overex-
pression has markedly repressed cellular growth examined byics signiﬁcantly inhibited cellular migration in HuH-7 cells while miR-155 mimics
signiﬁcantly promoted cellular migration compared to miR-615-5p mimicked cells
ked cells. (b) miR-615-5p mimics signiﬁcantly inhibited cellular migration in HepG2
e of the original scratch. Inhibitors of miR-615-5p signiﬁcantly promoted cellular
while miR-155 inhibitors suppressed migration signiﬁcantly compared to miR-155
alysis.
Fig. 5. Bioinformatics analysis for the binding between miR-615-5p and IGF-II; (a) Schematic representation for the 30UTR of IGF-II transcript showing the exact position of
binding to miR-615-5p. (b) Table for different binding sequences in the 30UTR of IGF-II for miR-615-5p. Note that miR-615-5p seeding sequence is the same for all binding
sites.
Fig. 6. IGF-II transcript as a common putative target of miR-615-5p; In HuH-7 and HepG2 cells: IGF-II mRNA expression was drastically suppressed upon mimicking of miR-
615-5p compared to controls while inhibitors of miR-615-5p showed increased expression of IGF-II transcript levels compared to mimicked cells. IGF-II decreased upon using
siRNAs against IGF-II compared to controls. One-way analysis of variance (ANOVA) was performed.
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155 which markedly induced proliferation and viability (Fig. 3). So
miR-615-5p simulates both miR-122 and miR-199a/b-3p and they
resulted in a potent HCC proliferation suppression [19,20]. miR-
615-5p have also suppressed HCC migration in contrast to miR-
155 which increased the migration (Fig. 4). So miR-615-5p acted
like the tumor suppressor miR-338-3p and miR-198 in inhibiting
HCC migration and invasion [21,22]. While miR-155 results were
consistent with those previously obtained in promoting cellularmigration and metastasis [8]. We further used anatagomirs for
miR-615-5p to recover its inhibitory effect on the cell lines which
showed increased proliferation and migration while antagonizing
miR-155 showed repressed proliferative and migratory effect on
the same cell lines.
Using in silico prediction for miR-615-5p downstream targets,
we found that IGF-II as one of the potential targets for miR-615-
5p. IGF-II is a pivotal mitogen in HCC that is frequently overexpres-
sed in HCC and associates with hyperproliferation and tumor cell
Fig. 7. Correlation analysis between miR-615-5p and IGF-II mRNA expressions in
HCC tissues; Values of miR-615-5p and IGF-II mRNA RQ in HCC tissues were
analyzed using Pearson method of correlation. An inverse correlation was found
with Pearson r = 0.468 (P = 0.0371).
Fig. 8. IGF-II is a direct target of miR-615-5p; miR-615-5p mimics and inhibitors
were co-transfected with pmiRGLO–insert or pmiRGLO + insert. Upon miR-615-5p
mimics co-transfection, luciferase activity was inhibited by 19.4% in cells with the
pmiRGLO + insert compared to cells transfected with the pmiRGLO–insert
(P < 0.0001). Upon miR-615-5p inhibitors co-transfection, luciferase activity was
increased by 9% compared to cells transfected pmiRGLO-insert (P = 0.064) and by
28% compared to pmiRGLO + insert co-transfected with miR-615-5p mimics
(P = 0.0007).
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bind to 5 regions in the 30UTR of the IGF-II mRNA by hitting with
high binding scores by the same seed sequence (Fig. 5). Over-
expressing miR-615-5p did not only reduce IGF-II transcript levels,
but also phenocopied the effects of IGF-II knock down by siRNAs
[23,25]. Using antagomirs for miR-615-5p, we were able to recover
the inhibitory effect of miR-615-5p on IGF-II (Fig. 6). That was fur-
ther supported by the shown inverse correlation between miR-
615-5p and IGF-II in HCC tissues (Fig. 7). Although miR-615-5p
was found to be expressed only in cancerous and cirrhotic tissues,
but its expression was minimal in a way that cannot harness the
overexpression of IGF-II (as an insufﬁcient compensatory eleva-
tion). With the exception of a single descriptive study that exam-
ined the expression of miR-615 in prostate cancer [16], our
results are the ﬁrst to reveal the expression/function of miR-615-
5p in HCC. We have shown that IGF-II is a direct target to miR-
615-5p represented in the signiﬁcant repression of luciferase activ-
ity upon miR-615-5p mimics co-transfection with the construct
harboring the IGF-II 30UTR target region of miR-615-5p (Fig. 8).
In conclusion, our data suggests that miR-615-5p might poten-
tially serve as novel tumor suppressor microRNA in HCC. We showthat miR-615-5p is restrictedly expressed in cirrhotic and HCC tis-
sues (with higher abundance) but not in healthy liver tissues. miR-
615-5p expression was inversely correlated with IGF-II mRNA
expression in human HCC liver tissues. Furthermore, we have
shown that IGF-II 30UTR is a direct target for miR-615-5p that
showed signiﬁcant decrease in cell proliferation and migration
upon its forced expression. Our results highly suggest miR-615-
5p as promising tumor suppressor microRNA and might be a po-
tential HCC diagnostic marker.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.febslet.
2012.06.054.References
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